Healthcare
Organogenesis Holdings Inc.(ORGO)
Live Price
Offline$2.44
+4.27% today
1Y Change
-31.36%
Window
Jun 25, 2025 โ Jun 23, 2026
- Market Cap
- $330.00M
- Revenue Growth
- +17.0%
- EPS Growth
- +2353.5%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 25, 2025 โ Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Organogenesis Holdings Inc. (ORGO) is a Healthcare stock with a market cap of $330.00M and listed on NASDAQ. The stock last traded around $2.44 and down 31.4% across the available one-year price window (Jun 25, 2025 โ Jun 23, 2026). Baseline metrics include revenue growth of +17.0%, EPS growth of +2353.5%, a dividend yield of 0.0%. What stands out right now is revenue +17.0%, EPS +2353.5%, free cash flow -685.7% with operating margin 8.3% and ROIC 7.0%. Valuation is more restrained than many high-expectation growth names at P/E 8.8 and price/sales 0.6. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines ORGO price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+17.0% vs +7.6% peer median
Operating Margin
Below sector median
+8.3% vs +19.4% peer median
P/E
Below sector median
8.8 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +17.0% and EPS at +2353.5%, with operating margin around 8.3%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +13.6% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | -6.9% | +2.7% | -9.7% |
2026 Feb 26, 2026 | +44.2% | -13.2% | -21.6% | -34.6% |
2025 Nov 6, 2025 | -14.3% | +44.7% | +59.6% | +21.9% |
Benchmark Edge
ORGO vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
ORGO
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
ORGO Max Drawdown
-65.75%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for ORGO and SPY.
Company Overview
Organogenesis Holdings Inc.
NASDAQ Capital Market
Organogenesis Holdings Inc., a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering tissue includes both amnion and chorion membranes for spongy/intermediate layer intact; PuraPly , a antimicrobial barrier that enables conformability and fluid drainage; and Novachor, an amniotic membrane wound covering in which viable cells, growth factors/cytokines, and ECM proteins are preserved. Its surgical and sports medicine products comprise NuCel, a dehydrated placental tissue surgically applied to the target tissue to support native healing; ReNu, a cryopreserved suspension used to support healing of soft tissues; and FiberOS and OCMP used as a bone void filler primarily in orthopedic and neurosurgical applications. The company's pipeline products include PuraPly XT and PuraPly MZ to treat chronic, acute, and open wounds; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales force and independent agencies. The company was founded in 1985 and is headquartered in Canton, Massachusetts.
- Leadership
- Gary S. Gillheeney
- IPO Date
- Jan 5, 2017
- Employees
- 869
- Street Address
- 85 Dan Road
- Mailing
- Canton, MA, 02021
- Region
- Canton, MA, US
- Reporting Currency
- USD
- Investor Line
- 781 575 0775
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 8.8
- EV/EBITDA
- 4.8
- Price/Sales
- 0.6
- Price/Book
- 0.8
Growth
- Revenue
- +17.0%
- EPS
- +2353.5%
- Free Cash Flow
- -685.7%
Profitability
- Gross Margin
- 74.4%
- Operating Margin
- 8.3%
- Net Margin
- 6.6%
- ROE
- 9.6%
- ROIC
- 7.0%
Balance Sheet
- Debt/Equity
- 0.31
- Current Ratio
- 3.62
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.